Contact Center Industry News

TMCNet:  Research and Markets: Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled

[May 07, 2014]

Research and Markets: Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles/records featured in thereport undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Involved:

  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • California Stem Cell, Inc.
  • Cell Therapeutics, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • EGEN, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Lee's Pharmaceutical Holdings Limited
  • MEI Pharma, Inc.
  • MabVax Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OncoMed Pharmaceuticals, Inc.
  • Oncolytics Biotech Inc.
  • Oxford BioMedica plc
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • Recepta Biopharma S.A.
  • Spectrum (News - Alert) Pharmaceuticals, Inc.
  • Synta Pharmaceuticals Corp.
  • TRION Pharma GmbH

Drug Profiles:

  • pazopanib hydrochloride
  • trebananib
  • paclitaxel poliglumex
  • paclitaxel
  • MEK-162
  • idronoxil
  • trabectedin
  • alisertib
  • dalantercept
  • elesclomol
  • TroVax
  • ramucirumab
  • pelareorep
  • nintedanib
  • catumaxomab
  • CRLX-101
  • VTX-2337
  • gimatecan
  • exatecan mesylate
  • RebmAb-100
  • EGEN-001
  • NSC-748933
  • INCB-24360
  • birinapant
  • rucaparib
  • metformin
  • Cancer Stem Cell Therapy
  • DPX-Survivac
  • ganetespib
  • pralatrexate

For more information visit

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...